Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,801-1,850 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__88_A5,2 | Lung | Primary cancer | 4,071 | Tumor/Malignant | 34.7% | 0.48 | 0.87 |
| NSCLC_38242124__IMC__88_A5,3 | Lung | Primary cancer | 4,953 | Immune | 35.5% | 0.92 | 0.23 |
| NSCLC_38242124__IMC__88_A5,4 | Lung | Primary cancer | 2,985 | Stromal | 37.8% | 0.85 | 0.41 |
| NSCLC_38242124__IMC__88_A5,5 | Lung | Primary cancer | 1,331 | Stromal | 27.8% | 0.61 | 0.79 |
| NSCLC_38242124__IMC__88_A5,6 | Lung | Primary cancer | 2,916 | Immune | 49.9% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_A5,8 | Lung | Primary cancer | 4,174 | Tumor/Malignant | 36.7% | 0.76 | 0.53 |
| NSCLC_38242124__IMC__88_A5,9 | Lung | Primary cancer | 2,590 | Tumor/Malignant | 80.8% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_A6,1 | Lung | Primary cancer | 4,214 | Tumor/Malignant | 43.1% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__88_A6,10 | Lung | Primary cancer | 2,671 | Tumor/Malignant | 72.0% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_A6,11 | Lung | Primary cancer | 3,657 | Tumor/Malignant | 68.9% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__88_A6,12 | Lung | Primary cancer | 3,303 | Tumor/Malignant | 47.8% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__88_A6,13 | Lung | Primary cancer | 816 | Stromal | 33.6% | 0.85 | 0.42 |
| NSCLC_38242124__IMC__88_A6,15 | Lung | Primary cancer | 3,624 | Tumor/Malignant | 32.1% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__88_A6,16 | Lung | Primary cancer | 3,966 | Tumor/Malignant | 43.1% | 0.96 | 0.15 |
| NSCLC_38242124__IMC__88_A6,3 | Lung | Primary cancer | 4,381 | Tumor/Malignant | 60.7% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_A6,4 | Lung | Primary cancer | 2,808 | Stromal | 29.1% | 0.95 | 0.21 |
| NSCLC_38242124__IMC__88_A6,5 | Lung | Primary cancer | 3,515 | Tumor/Malignant | 38.9% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_A6,6 | Lung | Primary cancer | 1,767 | Other | 22.4% | 0.45 | 0.92 |
| NSCLC_38242124__IMC__88_A6,8 | Lung | Primary cancer | 3,256 | Tumor/Malignant | 44.1% | 0.94 | 0.16 |
| NSCLC_38242124__IMC__88_A6,9 | Lung | Primary cancer | 3,337 | Tumor/Malignant | 82.4% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_A7,1 | Lung | Primary cancer | 3,240 | Stromal | 26.5% | 0.80 | 0.53 |
| NSCLC_38242124__IMC__88_A7,10 | Lung | Primary cancer | 2,113 | Tumor/Malignant | 53.7% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__88_A7,11 | Lung | Primary cancer | 3,179 | Tumor/Malignant | 50.0% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__88_A7,12 | Lung | Primary cancer | 861 | Stromal | 28.5% | 0.69 | 0.72 |
| NSCLC_38242124__IMC__88_A7,13 | Lung | Primary cancer | 3,282 | Tumor/Malignant | 42.5% | 0.95 | 0.23 |
| NSCLC_38242124__IMC__88_A7,14 | Lung | Primary cancer | 1,858 | Stromal | 39.3% | 0.79 | 0.49 |
| NSCLC_38242124__IMC__88_A7,15 | Lung | Primary cancer | 3,912 | Tumor/Malignant | 46.1% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__88_A7,16 | Lung | Primary cancer | 3,866 | Tumor/Malignant | 59.4% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__88_A7,2 | Lung | Primary cancer | 2,931 | Tumor/Malignant | 35.0% | 0.83 | 0.46 |
| NSCLC_38242124__IMC__88_A7,3 | Lung | Primary cancer | 3,583 | Tumor/Malignant | 55.3% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__88_A7,4 | Lung | Primary cancer | 2,848 | Stromal | 35.4% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_A7,5 | Lung | Primary cancer | 2,444 | Tumor/Malignant | 57.0% | 0.94 | 0.15 |
| NSCLC_38242124__IMC__88_A7,6 | Lung | Primary cancer | 4,004 | Tumor/Malignant | 71.9% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__88_A7,7 | Lung | Primary cancer | 3,483 | Tumor/Malignant | 81.7% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__88_A7,8 | Lung | Primary cancer | 3,840 | Tumor/Malignant | 92.0% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__88_A7,9 | Lung | Primary cancer | 2,058 | Other | 31.5% | 0.58 | 0.74 |
| NSCLC_38242124__IMC__88_A8,1 | Lung | Primary cancer | 3,439 | Tumor/Malignant | 33.0% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__88_A8,10 | Lung | Primary cancer | 2,277 | Tumor/Malignant | 43.0% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__88_A8,11 | Lung | Primary cancer | 2,263 | Tumor/Malignant | 46.6% | 0.92 | 0.31 |
| NSCLC_38242124__IMC__88_A8,12 | Lung | Primary cancer | 2,130 | Stromal | 41.2% | 0.52 | 0.91 |
| NSCLC_38242124__IMC__88_A8,13 | Lung | Primary cancer | 2,935 | Tumor/Malignant | 38.0% | 0.52 | 0.73 |
| NSCLC_38242124__IMC__88_A8,14 | Lung | Primary cancer | 2,259 | Tumor/Malignant | 51.0% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__88_A8,15 | Lung | Primary cancer | 2,669 | Tumor/Malignant | 52.2% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__88_A8,2 | Lung | Primary cancer | 3,251 | Tumor/Malignant | 39.0% | 0.94 | 0.20 |
| NSCLC_38242124__IMC__88_A8,3 | Lung | Primary cancer | 2,827 | Tumor/Malignant | 64.1% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_A8,4 | Lung | Primary cancer | 2,008 | Stromal | 34.3% | 0.63 | 0.72 |
| NSCLC_38242124__IMC__88_A8,5 | Lung | Primary cancer | 2,592 | Tumor/Malignant | 40.7% | 0.92 | 0.27 |
| NSCLC_38242124__IMC__88_A8,6 | Lung | Primary cancer | 952 | Tumor/Malignant | 68.4% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__88_A8,7 | Lung | Primary cancer | 3,087 | Tumor/Malignant | 78.1% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__88_A8,8 | Lung | Primary cancer | 3,789 | Tumor/Malignant | 87.0% | 0.99 | 0.04 |